ImmunoGen, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenues
License and milestone fees
Non-cash royalty revenue related to the sale of future royalties
Research and development support
Clinical materials revenue
Product revenue, net
Total revenues

Cost and operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Restructuring charge
Total cost and operating expenses
Loss from operations
Investment income, net
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes
Interest expense on convertible senior notes
Other (expense) income, net
Net loss before income taxes
Income tax expense
Net loss
Basic net loss per common share
Diluted net loss per common share
Basic weighted average common shares outstanding (in shares)
Diluted weighted average common shares outstanding (in shares)
Total comprehensive loss

Comments